Shows antitumor and anti-inflammatory activities. Potent non-redox, noncompetitive 5-lipoxygenase and topoisomerase I and IIa inhibitor leading to apoptosis. 10-times more potent than 3-O-acetyl-β-boswellic acid (Prod. No. ALX-350-308). Exhibits in vivo efficacy in tumor growth and inhibition.
Product Details
Alternative Name: | AKβBA |
|
Formula: | C32H48O5 |
|
MW: | 512.7 |
|
Source: | Isolated from Boswellia serrata. |
|
CAS: | 67416-61-9 |
|
Purity: | ≥98% (HPLC) |
|
Appearance: | White to off-white solid. |
|
Solubility: | Soluble in acetone, dichloromethane, diethyl ether or DMSO. |
|
Shipping: | Ambient |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stock solutions are stable for up to 3 months when stored at -20°C. |
|
Handling: | Protect from light. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Boswellic acids: biological actions and molecular targets: D. Poeckel & O. Werz; Curr. Med. Chem.
13, 3359 (2006), Review,
Abstract;
Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis: C. Anthoni, et al.; Am. J. Physiol. Gastrointest. Liver Physiol.
290, G1131 (2006),
Abstract;
Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid: M. Bishnoi, et al.; Indian J. Exp. Biol.
44, 128 (2006),
Abstract;
Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo: T. Syrovets, et al.; J. Biol. Chem.
280, 6170 (2005),
Abstract;
Full Text
Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes: A. Altmann, et al.; Br. J. Pharmacol.
141, 223 (2004),
Abstract;
Full Text
Boswellic acids activate p42(MAPK) and p38 MAPK and stimulate Ca(2+) mobilization: A. Altmann, et al.; BBRC
290, 185 (2002),
Abstract;
Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I: R.F. Hoernlein, et al.; J. Pharmacol. Exp. Ther.
288, 613 (1999),
Abstract;
Full Text